NO962006L - Substituerte benzyloksykarbonylguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som legemiddel inneholdende dem - Google Patents

Substituerte benzyloksykarbonylguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som legemiddel inneholdende dem

Info

Publication number
NO962006L
NO962006L NO962006A NO962006A NO962006L NO 962006 L NO962006 L NO 962006L NO 962006 A NO962006 A NO 962006A NO 962006 A NO962006 A NO 962006A NO 962006 L NO962006 L NO 962006L
Authority
NO
Norway
Prior art keywords
drug
diagnostic
preparation
well
benzyloxycarbonylguanidines
Prior art date
Application number
NO962006A
Other languages
English (en)
Other versions
NO306156B1 (no
NO962006D0 (no
Inventor
Heinz-Werner Kleemann
Joachim Brendel
Jan-Robert Schwark
Andreas Weichert
Hans-Jochen Lang
Udo Albus
Wolfgang Scholz
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO962006D0 publication Critical patent/NO962006D0/no
Publication of NO962006L publication Critical patent/NO962006L/no
Publication of NO306156B1 publication Critical patent/NO306156B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/10—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by doubly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
NO962006A 1995-05-17 1996-05-15 Substituerte benzyloksykarbonylguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum sÕvel som legemidler inneholdende disse NO306156B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19518073A DE19518073A1 (de) 1995-05-17 1995-05-17 Substituierte Benzyloxycarbonylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (3)

Publication Number Publication Date
NO962006D0 NO962006D0 (no) 1996-05-15
NO962006L true NO962006L (no) 1996-11-18
NO306156B1 NO306156B1 (no) 1999-09-27

Family

ID=7762133

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962006A NO306156B1 (no) 1995-05-17 1996-05-15 Substituerte benzyloksykarbonylguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum sÕvel som legemidler inneholdende disse

Country Status (29)

Country Link
US (2) US5753710A (no)
EP (1) EP0748795B1 (no)
JP (1) JP3962110B2 (no)
KR (1) KR960040130A (no)
CN (1) CN1062555C (no)
AR (1) AR002741A1 (no)
AT (1) ATE195726T1 (no)
AU (1) AU701567B2 (no)
BR (1) BR9602337A (no)
CA (1) CA2176796C (no)
CZ (1) CZ288332B6 (no)
DE (2) DE19518073A1 (no)
DK (1) DK0748795T3 (no)
ES (1) ES2149403T3 (no)
GR (1) GR3034573T3 (no)
HR (1) HRP960221B1 (no)
HU (1) HUP9601321A3 (no)
IL (1) IL118278A (no)
MY (1) MY115805A (no)
NO (1) NO306156B1 (no)
NZ (1) NZ286583A (no)
PL (1) PL183629B1 (no)
PT (1) PT748795E (no)
RU (1) RU2188191C2 (no)
SI (1) SI0748795T1 (no)
SK (1) SK282010B6 (no)
TR (1) TR199600400A2 (no)
TW (1) TW355705B (no)
ZA (1) ZA963893B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19960204A1 (de) * 1999-12-14 2001-06-28 Aventis Pharma Gmbh Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6740776B2 (en) 2001-07-16 2004-05-25 Novartis Ag Air oxidation of an aromatic aldehyde to an aromatic acid
ME02465B (me) * 2011-03-15 2017-02-20 Astellas Pharma Inc Jedinjenje gvanidina
WO2013113791A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
BR112014018909A8 (pt) 2012-02-03 2017-07-11 Basf Se Compostos, processo para a preparação dos compostos, composição agroquímica, método para o combate dos fungos, utilização dos compostos e semente
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
JP2015508752A (ja) 2012-02-03 2015-03-23 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性ピリミジン化合物
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
US10202337B2 (en) * 2014-03-28 2019-02-12 Kaneka Corporation Method for producing tri-carbobenzoxy-arginine
UA121930C2 (uk) * 2016-05-12 2020-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Піридинільні похідні, фармацевтичні композиції та їх застосування як інгібіторів аос3
CN109111376B (zh) * 2018-09-18 2021-09-14 四川医立特生物医药有限公司 一种2,5-双脱氧链霉胺衍生物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734904A (en) * 1956-02-14 Xcxnhxc-nh
BE844832A (fr) * 1976-08-03 1977-02-03 Rorer Inc William H Nouvelles amidinourees, leur preparation et leur emploi
GB8523606D0 (en) * 1985-09-25 1985-10-30 Shell Int Research Pesticidal benzoylurea compounds
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
ES2107698T3 (es) * 1993-02-20 1997-12-01 Hoechst Ag Benzoilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento, como inhibidores del intercambio celular de na+/h+ o como agente de diagnostico, asi como medicamento que las contiene.
DE4328869A1 (de) * 1993-08-27 1995-03-02 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
HUP9601321A3 (en) 1998-04-28
IL118278A (en) 2001-06-14
JP3962110B2 (ja) 2007-08-22
AU701567B2 (en) 1999-02-04
MY115805A (en) 2003-09-30
HRP960221B1 (en) 2002-02-28
CZ288332B6 (en) 2001-05-16
HUP9601321A2 (en) 1997-05-28
JPH08311012A (ja) 1996-11-26
SK62996A3 (en) 1996-12-04
NO306156B1 (no) 1999-09-27
ES2149403T3 (es) 2000-11-01
IL118278A0 (en) 1996-09-12
TW355705B (en) 1999-04-11
NZ286583A (en) 1997-10-24
US6022899A (en) 2000-02-08
DK0748795T3 (da) 2000-12-18
HU9601321D0 (en) 1996-07-29
ATE195726T1 (de) 2000-09-15
ZA963893B (en) 1997-11-17
TR199600400A2 (tr) 1997-03-21
HRP960221A2 (en) 1997-12-31
NO962006D0 (no) 1996-05-15
RU2188191C2 (ru) 2002-08-27
SI0748795T1 (en) 2001-02-28
EP0748795A3 (de) 1997-03-19
CN1062555C (zh) 2001-02-28
PL314253A1 (en) 1996-11-25
EP0748795A2 (de) 1996-12-18
KR960040130A (ko) 1996-12-17
DE19518073A1 (de) 1996-11-21
CA2176796C (en) 2009-09-29
AU5229496A (en) 1996-11-28
CN1145360A (zh) 1997-03-19
PL183629B1 (pl) 2002-06-28
EP0748795B1 (de) 2000-08-23
PT748795E (pt) 2001-01-31
US5753710A (en) 1998-05-19
BR9602337A (pt) 1998-09-01
DE59605782D1 (de) 2000-09-28
GR3034573T3 (en) 2001-01-31
SK282010B6 (sk) 2001-10-08
AR002741A1 (es) 1998-04-29
CA2176796A1 (en) 1996-11-18
CZ141596A3 (en) 1997-08-13

Similar Documents

Publication Publication Date Title
NO964639L (no) Substituerte sulfonimidamider, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsen
NO973923D0 (no) Nye taxoider, deres fremstilling samt farmasöytiske preparater inneholdende forbindelsene
TR25501A (tr) Kalorisi azaltilmis yaglari ihtiva eden tatlandir- ilmis sekerleme bilesimlerini kivamina getirmek icin islem ve böyle hazirlanan kivamlandirilmis mamuller.
NO973850L (no) Fenylsubstituerte alkenylkarboksylsyreguanidider, fremgangsmåter for deres fremstilling, deres anvendelse som medikament eller diagnostika såvel som medikamenter inneholdende dem
DK0807629T3 (da) Sulfonamidsubstituerede chromaner, fremgangsmåde til fremstilling deraf, anvendelse deraf som medikamenter eller diagnostiske midler samt medikamenter indeholdende dem
NO962006L (no) Substituerte benzyloksykarbonylguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som legemiddel inneholdende dem
NO962063D0 (no) Fluorfenylsubstituerte alkenylkarboksylsyre-guanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som medikament inneholdende dem
NO960364D0 (no) Basisk-substituerte benzolguanidiner, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsen
NO20022801D0 (no) Substituerte norbornylaminoderivater, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikumsåvel som medikamenter inneholdende disse
NO952596D0 (no) Orto-aminosubstituerte benzoylguandiner, fremgangsmåter for deres fremstilling, deres anvendelse som legemiddel eller diagnostikum såvel som medikamenter som inneholder dem
NO972433L (no) Substituerte 2-naftoylguanidiner, fremgangsmåter for deres fremstilling, deres anvendelse som medikament eller diagnostikum samt medikamenter inneholdende forbindelsene
NO964053D0 (no) Substituerte benzoylguanidiner, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikamenter inneholdende forbindelsene
NO960627L (no) Substituerte benzolsulfonylurinstoffer, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum samt legemidler inneholdende dem
NO980694D0 (no) Sulfonamidsubstituerte kromaner, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostika såvel som medikamenter inneholdende dem
NO962999D0 (no) Fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum, såvel som medikament inneholdende dem
DK1097140T3 (da) Imidazolderivater med biphenylsubstitution, fremgangsmåde til deres fremstilling, deres anvendelse som lægemiddel eller diagnostikum og lægemiddel som indeholder dem
NO973486L (no) Substituerte indanylidinacetylguanidiner, fremgangsmåte for fremstilling derav, deres anvendelse som medikamenter eller diagnostikum og medikamenter inneholdende forbindelsene
NO903347L (no) 14,17alfa-ethano- og ethanooestratriener, fremgangsmaate forfremstilling av disse forbindelser, saavel som anvendelse av dem for fremstilling av legemidler.
DK0763535T3 (da) Piperidinylmethyloxazolidin-2-on-derivater, deres fremstilling og deres anvendelse som centralnervesystem-aktive forbindelser
DK0810205T3 (da) Substituerede 1-naphthoylguanidiner, fremgangsmåde til deres fremstiling, deres anvendelse som lægemiddel eller diagnostisk middel samt lægemiddel indeholdende dem
NO983577L (no) Sulfonamidsubstituerte forbindelser, fremgangsmÕter for deres fremstilling, deres anvendelse som medikament eller diagnostikum, samt medikament inneholdende forbindelsen
NO964903D0 (no) Substituerte benzendikarboksylsyre-diguanidid, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som medikament inneholdende dem
NO970697L (no) Substituerte tiofenalkenylkarboksylsyreguanidider, fremgangsmåter for deres fremstilling, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsene
NO980564L (no) Sulfonamid-substituerte forbindelser, fremgangsmÕte for fremstilling, anvendelse som medikament eller diagnostikum samt oppnÕdd medikament er beskrevet
NO964904D0 (no) Substituerte benzendikarboksylsyre-diguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum såvel som medikamenter inneholdende dem

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees